|
Alcoholic Intoxication, Chronic
|
0.520 |
Biomarker
|
disease |
BEFREE |
To investigate the mechanism of acamprosate efficacy, the authors employ a pharmacoproteomics approach using an animal model of alcoholism, type 1 equilibrative nucleoside transporter (ENT1) null mice.
|
29437267 |
2018 |
|
Alcoholic Intoxication, Chronic
|
0.520 |
GeneticVariation
|
disease |
BEFREE |
Together with the functional data, our findings suggest a potential contribution of a genetic variant of ENT1 to the development of alcoholism with increased risk of alcohol withdrawal-induced seizures in humans.
|
21283641 |
2011 |
|
Alcoholic Intoxication, Chronic
|
0.520 |
Biomarker
|
disease |
PSYGENET |
Together with the functional data, our findings suggest a potential contribution of a genetic variant of ENT1 to the development of alcoholism with increased risk of alcohol withdrawal-induced seizures in humans.
|
21283641 |
2011 |
|
Alcoholic Intoxication, Chronic
|
0.520 |
Biomarker
|
disease |
PSYGENET |
Since elevated glutamate signaling, especially in the nucleus accumbens (NAc), is implicated in several aspects of alcoholism, we utilized mice lacking type 1 equilibrative nucleoside transporter (ENT1), which exhibit increased glutamate levels in the NAc as well as increased ethanol drinking behaviors.
|
21172405 |
2011 |
|
Alcoholic Intoxication, Chronic
|
0.520 |
Biomarker
|
disease |
MGD |
The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference.
|
15258586 |
2004 |
|
Malignant neoplasm of pancreas
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
|
31711924 |
2020 |
|
Malignant neoplasm of pancreas
|
0.370 |
Biomarker
|
disease |
BEFREE |
DPD and hENT1 immunohistochemistry and scoring was completed on tumour cores from 238 patients with pancreatic cancer in the ESPAC-3(v2) trial, randomised to either postoperative gemcitabine or 5-fluorouracil/folinic acid (5FU/FA).
|
29515256 |
2018 |
|
Malignant neoplasm of pancreas
|
0.370 |
Biomarker
|
disease |
BEFREE |
Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy.
|
28693211 |
2017 |
|
Malignant neoplasm of pancreas
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
The reports on the relationship between SLC29A1 expression and prognosis of patients with pancreatic cancer are currently rather conflicting.
|
24280569 |
2014 |
|
Malignant neoplasm of pancreas
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
|
18992248 |
2009 |
|
Malignant neoplasm of pancreas
|
0.370 |
Biomarker
|
disease |
CTD_human |
Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer.
|
18728667 |
2008 |
|
Malignant neoplasm of pancreas
|
0.370 |
Biomarker
|
disease |
BEFREE |
Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
|
17695509 |
2007 |
|
Malignant neoplasm of pancreas
|
0.370 |
Biomarker
|
disease |
BEFREE |
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
|
16585222 |
2006 |
|
Colorectal Carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
Human equilibrative nucleoside transporters (hENT) 1 and 2, encoded by SLC29A1 and SLC29A2, permit the bidirectional passage of nucleoside analogues into cells and may correlate with clinical responses to chemotherapy in patients with colorectal cancer (CRC).
|
28218790 |
2017 |
|
Huntington Disease
|
0.320 |
Biomarker
|
disease |
BEFREE |
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
|
28069792 |
2017 |
|
Colorectal Carcinoma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Alternative transcript of SLC29A1 (NM_001078177) was up-regulated only in CRC samples, but not in the other tested tumor types.
|
28105922 |
2016 |
|
Huntington Disease
|
0.320 |
Biomarker
|
disease |
BEFREE |
The present study demonstrates that ENT1 and adenosine constitute biomarkers of the initial stages of neurodegeneration in HD disease and also predicts that ENT1 could constitute a new therapeutic target to delay the progression of the disease.
|
27567601 |
2016 |
|
Huntington Disease
|
0.320 |
Biomarker
|
disease |
CTD_human |
The present study demonstrates that ENT1 and adenosine constitute biomarkers of the initial stages of neurodegeneration in HD disease and also predicts that ENT1 could constitute a new therapeutic target to delay the progression of the disease.
|
27567601 |
2016 |
|
Colorectal Carcinoma
|
0.320 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Alcohol Withdrawal Seizures
|
0.310 |
Biomarker
|
disease |
CTD_human |
Together with the functional data, our findings suggest a potential contribution of a genetic variant of ENT1 to the development of alcoholism with increased risk of alcohol withdrawal-induced seizures in humans.
|
21283641 |
2011 |
|
Alcohol Withdrawal Seizures
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Together with the functional data, our findings suggest a potential contribution of a genetic variant of ENT1 to the development of alcoholism with increased risk of alcohol withdrawal-induced seizures in humans.
|
21283641 |
2011 |
|
Huntington Disease, Late Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.
|
27567601 |
2016 |
|
Akinetic-Rigid Variant of Huntington Disease
|
0.300 |
Biomarker
|
disease |
CTD_human |
Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.
|
27567601 |
2016 |
|
Juvenile Huntington Disease
|
0.300 |
Biomarker
|
disease |
CTD_human |
Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.
|
27567601 |
2016 |
|
Alcohol Withdrawal-Induced Major Motor Seizure
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Functional role of the polymorphic 647 T/C variant of ENT1 (SLC29A1) and its association with alcohol withdrawal seizures.
|
21283641 |
2011 |